Page 52 - วารสารกรมการแพทย์แผนไทยฯ ปีที่ 14 ฉบับที่ 3

270

15. Singh YN, Singh NN. Therapeutic potential of kava in the 28. Watkins LL, Connor KM, Davidson JR. Effect of kava
treatment of anxiety disorders. CNS Drugs. 2002;16(11): extract on vagal cardiac control in generalized anxiety
731-43. disorder: preliminary findings. J Psychopharmacol. 2001;
16. Clouatre DL. Kava kava: examining new reports of toxicity. 15(4):283-6.
Toxicol Lett. 2004;150(1):85-96. 29. Boerner RJ, Sommer H, Berger W, Kuhn U, Schmidt U,
17. Magura EI, Kopanitsa MV, Gleitz J, Peters T, Krishtal OA. Mannel M. Kava-Kava extract LI 150 is as effective as
Kava extract ingredients, (+)-methysticin and (+/-)-kavain opipramol and buspirone in generalised anxiety disorder-
inhibit voltage-operated Na(+)-channels in rat CA1 an 8-week randomized, double-blind multi-centre clinical
hippocampal neurons. Neuroscience. 1997;81(2):345-51. trial in 129 out-patients. Phytomedicine. 2003;10 Suppl
18. Gleitz J, Tosch C, Beile A, Peters T. The protective action 4:38-49.
of tetrodotoxin and (+/-)-kavain on anaerobic glycolysis, 30. Sarris J, Kavanagh DJ, Byrne G, Bone KM, Adams J,
ATP content and intracellular Na+ and Ca2+ of anoxic Deed G. The Kava Anxiety Depression Spectrum Study
brain vesicles. Neuropharmacology. 1996;35(12):1743-52. (KADSS): a randomized, placebo-controlled crossover trial
19. Martin HB, McCallum M, Stofer WD, Eichinger MR. Kavain using an aqueous extract of Piper methysticum.
attenuates vascular contractility through inhibition of calcium Psychopharmacology (Berl). 2009;205(3):399-407.
channels. Planta Med. 2002;68(9):784-9. 31. Connor KM, Davidson JR. A placebo-controlled study of
20. Baum SS, Hill R, Rommelspacher H. Effect of kava extract Kava kava in generalized anxiety disorder. Int Clin
and individual kavapyrones on neurotransmitter levels in Psychopharmacol. 2002;17(4):185-8.
the nucleus accumbens of rats. Prog Neuropsycho- 32. Gastpar M, Klimm HD. Treatment of anxiety, tension and
pharmacol Biol Psychiatry. 1998;22(7):1105-20. restlessness states with Kava special extract WS 1490 in
21. Seitz U, Schule A, Gleitz J. [3H]-monoamine uptake general practice: a randomized placebo-controlled double-
inhibition properties of kava pyrones. Planta Med. 1997; blind multicenter trial. Phytomedicine. 2003;10(8):631-9.
63(6):548-9. 33. Jacobs BP, Bent S, Tice JA, Blackwell T, Cummings SR.
22. Boonen G, Haberlein H. Influence of genuine kavapyrone An internet-based randomized, placebo-controlled trial of
enantiomers on the GABA-A binding site. Planta Med. kava and valerian for anxiety and insomnia. Medicine.
1998;64(6):504-6. 2005;84(4):197-207.
23. Jussofie A, Schmiz A, Hiemke C. Kavapyrone enriched 34. Poolsup N, Li Wan Po A, Knight TL. Pharmacogenetics
extract from Piper methysticum as modulator of the GABA and psychopharmacotherapy. J Clin Pharm Ther. 2000;
binding site in different regions of rat brain. Psycho- 25(3):197-220.
pharmacology (Berl). 1994;116(4):469-74. 35. Wanwimolruk S, Bhawan S, Coville PF, Chalcroft SC.
24. Yuan CS, Dey L, Wang A, Mehendale S, Xie JT, Aung Genetic polymorphism of debrisoquine (CYP2D6) and
HH, et al. Kavalactones and dihydrokavain modulate proguanil (CYP2C19) in South Pacific Polynesian
GABAergic activity in a rat gastric-brainstem preparation. populations. Eur J Clin Pharmacol. 1998;54(5):431-5.
Planta Med. 2002;68(12):1092-6. 36. Sarris J, LaPorte E, Schweitzer I. Kava: a comprehensive
25. Rex A, Morgenstern E, Fink H. Anxiolytic-like effects of review of efficacy, safety, and psychopharmacology. Aust
kava-kava in the elevated plus maze test-a comparison N Z J Psychiatry. 2011;45(1):27-35.
with diazepam. Prog Neuropsychopharmacol Biol 37. Wohlmuth H, Penman KG, Pearson T, Lehmann RP.
Psychiatry. 2002;26(5):855-60. Pharmacognosy and chemotypes of passionflower
26. Volz HP, Kieser M. Kava-kava extract WS 1490 versus (Passiflora incarnata L.). Biological & Pharmaceutical
placebo in anxiety disorders-a randomized placebo- Bulletin. 2010;33(6):1015-8.
controlled 25-week outpatient trial. Pharmacopsychiatry. 38. Dhawan K, Kumar S, Sharma A. Anti-anxiety studies on
1997;30(1):1-5. extracts of Passiflora incarnata Linneaus. J Ethnopharmacol.
27. Malsch U, Kieser M. Efficacy of kava-kava in the treatment 2001;78(2-3):165-70.
of non-psychotic anxiety, following pretreatment with 39. Appel K, Rose T, Fiebich B, Kammler T, Hoffmann C,
benzodiazepines. Psychopharmacology (Berl). 2001;157 Weiss G. Modulation of the gamma-aminobutyric acid
(3):277-83. (GABA) system by Passiflora incarnata L. Phytother Res.